Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 9/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487742 | 0.82 | ITGA2B (0.45) | KDM4EITGA2BITGB3MAPTPKM | |
| SCHEMBL370044 | 0.78 | KDM4E (0.63) | KDM4EITGA2BITGB3MAPTGRIA2 | |
| SCHEMBL368216 | 0.76 | ITGA2B (0.47) | KDM4EITGA2BITGB3MAPTPKM | |
| SCHEMBL4474046 | 0.73 | ITGA2B (0.45) | KDM4EITGA2BITGB3MAPTPKM | |
| SCHEMBL11481979 | 0.69 | ALDH1A1 (0.56) | KDM4EMAPTGRIA2GRIN1GRIN2A | |
| SCHEMBL19557525 | 0.68 | MAPT (0.68) | KDM4EITGA2BITGB3MAPTPKM | |
| SCHEMBL19086817 | 0.67 | ITGB3 (0.56) | KDM4EITGA2BITGB3MAPTPKM | |
| SCHEMBL15260567 | 0.66 | BCHE (0.41) | KDM4EITGA2BITGB3MAPTPKM | |
| SCHEMBL4474040 | 0.65 | ITGB3 (0.54) | KDM4EITGA2BITGB3MAPTPKM | |
| SCHEMBL368965 | 0.64 | ITGA2B (0.47) | KDM4EITGA2BITGB3MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9532989-B2 | Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150374697-A1 | ORGANIC COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-12-31 | — | — | US | disclosed |
| US-9066948-B2 | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130251761-A1 | ORGANIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| EP-2593106-A1 | ORGANIC COMPOUNDS | Rockefeller University (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009688-A1 | ORGANIC COMPOUNDS | ROCKEFELLER UNIVERSITY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374697-A1 | ORGANIC COMPOUNDS | PLAT, ICAM1, VCAM1 | KDM4E 3520/4885ITGA2B 255/4885ITGB3 75/4885 |
| US-20130251761-A1 | ORGANIC COMPOUNDS | PLAT, ICAM1, VCAM1 | KDM4E 3520/4885ITGA2B 255/4885ITGB3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.